A therapeutic strategy of targeting IDH enzymes via small molecules in combination with targeted and/or conventional therapies could represent a Gordian knot solution and may meet more success than solely targeting genomic alterations in a heterogeneous tumor such as GBM. The gene discussed is IDH2; the disease is glioblastoma.